Biopharmaceutical company OrphoMed announced that the FDA has granted Fast Track status to speed development of its drug candidate for diarrhea-predominant irritable bowel syndrome.ORP-101, a ...

ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Ironwood Pharmaceuticals (formerly Microbia) today announced presentation of data from a pair of preclinical studies delineating the role that cyclic guanosine ...

Furthermore, keishikashakuyakuto—a kampo medicine clinically used for the treatment of IBS—normalized the intestinal motility change in cVSDS model mice. Our results indicate that cVSDS model mice ...

Conclusions Although the pathophysiology of IBS remains unclear, targeting the ECS may represent a promising strategy to modulate gut motility, visceral hyperalgesia, low-grade intestinal inflammation ...

OrphoMed Inc. completed a $39 million Series A financing, the capital of which they will use to accelerate clinical development of its lead candidate, ORP-101, a peripherally acting dimer, for the ...

ABSTRACT: The aim of our study was to assess in our context, the efficacy of Rifaxim in improving the symptoms of irritable bowel syndrome particularly in its diarrheal (IBS-D) or mixed (IBS-DC) ...

FRIDAY, June 7, 2019 (HealthDay News) — A greater number of intestinal and brain function abnormalities increases the burden of irritable bowel syndrome (IBS), according to a study recently published ...

Background Opioid-induced hyperalgesia (OIH) describes a paradoxical response where opioids given for pain instead result in an increased pain response.1 It has mostly been described when opioids are ...

Elaborating on their study, Prof. Saitoh says, "We focused on the cVSDS paradigm and evaluated the impact of emotional stress on intestinal conditions. We further assessed the paradigm's potential as ...